Andrew is a co-founder of KalVista Pharmaceuticals and its CEO. Prior to KalVista, Andrew held various senior management positions including Chief Executive, Vice President of Business Development and Director of Clinical and Regulatory Affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including mergers and acquisitions, national and international product licenses, IP and technology licenses, and R&D alliances.
Andrew received a BA from the University of Utah and an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
Martin Edwards previously served as Chair of KalVista when it was a privately held company. He is a member of the Board of Directors of Verona Pharma PLC, Reata Pharmaceuticals Inc., and Inozyme Pharma Inc. Dr. Edwards was Senior Partner at Novo Ventures between 2003 and 2020. Previously, he served as the CEO of ReNeuron Holdings, and was formerly Corporate VP and Global Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Earlier, he worked for six years in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton, NJ. Dr. Edwards was trained in physiology and medicine in Manchester UK. He was elected as a Member of the Royal Colleges of Physicians, a Member with Distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.
Brian J. G. Pereira
Brian J. G. Pereira is a veteran biopharmaceutical and healthcare leader with experience in financing and growing companies. He has been President & CEO of Visterra, Inc. since 2013 and continues to serve in this role after the acquisition by Otsuka in August 2018. He previously served as President & CEO of AMAG Pharmaceuticals where he raised four financing rounds at increasing valuations and built the clinical development, manufacturing, supply-chain and commercial infrastructure for Feraheme. Prior to AMAG Pharmaceuticals, he held senior roles at Tufts Medical Center, including President and CEO of a Tufts Medical Center Physician Organization and interim COO.
Brian is Chairman of the Board of Directors of Africa Healthcare Network and member of the Board of Visterra, Inc., and Cullinan Pearl Corp. He has previously served on the Board of several private and public companies. He serves on the Board of Directors of the America India Foundation and Board of Advisors of Life Sciences Cares. He was the Chairman of the Board of the Harvard-MIT Biomedical Enterprise Program and President and Board member of the National Kidney Foundation. Brian is an Adjunct Professor of Medicine at Tufts University School of Medicine and has authored over 200 published scientific articles. He received his medical degree (MBBS) from St. John’s Medical College, MD (Medicine) and DM (Nephrology) from the Post Graduate Institute and MBA from Kellogg School of Management at Northwestern University.
Daniel B. Soland
Daniel B. Soland most recently served as Chief Executive Officer of uniQure N.V., prior to that Senior Vice President and Chief Operating Officer of ViroPharma, and currently serves on the Boards of Directors of Acadia Pharmaceuticals and DBV Technologies. He previously served as President of Chiron Vaccines, and helped engineer a turnaround that contributed to the acquisition of Chiron by Novartis. Prior to that, he was President and Chief Executive Officer of Epigenesis Pharmaceuticals. At GlaxoSmithKline Biologicals, Mr. Soland served as Vice President and Director, Worldwide Marketing Operations. Earlier in his career, he held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.
Edward W. Unkart
Edward W. Unkart has served as a member of KalVista’s Board of Directors since the consummation of the Carbylan Therapeutics, Inc. transaction in 2016. From August 2006 to August 2009, Mr. Unkart served as a member of the Board of Directors of XTENT, a publicly traded manufacturer of drug-eluting stent systems, where he was the Chair of the company’s audit committee and a member of the nominating and governance committee. From October 2004 to June 2009, Mr. Unkart served as a member of the Board of Directors of VNUS Medical Technologies, a publicly traded medical device company, where he was the Chair of the company’s audit committee and a member of the compensation committee. From January 2005 to December 2008, Mr. Unkart served as Vice President of Finance and Administration and Chief Financial Officer of SurgRx; a manufacturer of medical devices. Mr. Unkart is a Certified Public Accountant and holds a BS and an MBA from Stanford University.